Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action (Q38058981)

27 August 2017

Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action (English)

1 reference

27 August 2017

1

Raoul Poupon

0 references

language of work or name

1 reference

1 September 2012

1 reference

Clinics and research in hepatology and gastroenterology

27 August 2017

1 reference

27 August 2017

36 Suppl 1

1 reference

27 August 2017

S3-12

1 reference

Identification of a nuclear receptor for bile acids

27 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Bile acids: natural ligands for an orphan nuclear receptor

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Endogenous bile acids are ligands for the nuclear receptor FXR/BAR

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Identification of membrane-type receptor for bile acids (M-BAR)

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

A G protein-coupled receptor responsive to bile acids

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Hepatic injury induced by bile salts: correlation between biochemical and morphological events

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Hydrophobic bile salts induce hepatocyte shrinkage via NADPH oxidase activation

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Bile salt-induced apoptosis involves NADPH oxidase isoform activation

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Bile acids induce inflammatory genes in hepatocytes: a novel mechanism of inflammation during obstructive cholestasis

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Effects of bile acids and cholestasis on major histocompatibility complex class I in human and rat hepatocytes

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Immunogenicity of rat hepatocytes in vivo: effect of cholestasis-induced changes in major histocompatibility complex expression

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Differential effects of chenodeoxycholic and ursodeoxycholic acids on interleukin 1, interleukin 6 and tumor necrosis factor-alpha production by monocytes

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Effect of cholestasis and bile acids on interferon-induced 2',5'-adenylate synthetase and NK cell activities.

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Bile acids modulate the interferon signalling pathway

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis?

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Clinical pharmacokinetics of therapeutic bile acids.

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Ursodeoxycholic acid in the treatment of cholesterol cholelithiasis. Part II.

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Intestinal absorption of the bile acid analogue 75Se-homocholic acid-taurine is increased in primary biliary cirrhosis, and reverts to normal during ursodeoxycholic acid administration

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Ileal absorption of bile acids in patients with chronic cholestasis: SeHCAT test results and effect of ursodeoxycholic acid (UDCA)

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Kinetics of hepatic bile acid handling in cholestatic liver disease: effect of ursodeoxycholic acid.

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Effect of ursodeoxycholic acid on the kinetics of the major hydrophobic bile acids in health and in chronic cholestatic liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Ursodeoxycholic acid therapy of chronic cholestatic conditions in adults and children.

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Cytokine-stimulated nitric oxide production inhibits adenylyl cyclase and cAMP-dependent secretion in cholangiocytes

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Proinflammatory cytokines inhibit secretion in rat bile duct epithelium.

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Abnormal expression of anion exchanger genes in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Assessment of biliary bicarbonate secretion in humans by positron emission tomography

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Mechanisms of action and therapeutic efficacy of ursodeoxycholic acid in cholestatic liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Ursodeoxycholic acid is conjugated with taurine to promote secretin-stimulated biliary hydrocholeresis in the normal rat.

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Ursodeoxycholic acid stimulates the formation of the bile canalicular network

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Molecular aspects of membrane stabilization by ursodeoxycholate [see comment]

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Ursodeoxycholic acid may inhibit deoxycholic acid-induced apoptosis by modulating mitochondrial transmembrane potential and reactive oxygen species production

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Ursodeoxycholic acid protects hepatocytes against oxidative injury via induction of antioxidants

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Ursodeoxycholic acid suppresses extent of lipid peroxidation in diseased liver in experimental cholestatic liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Effect of ursodeoxycholic acid on methionine adenosyltransferase activity and hepatic glutathione metabolism in rats

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Activation of the metallothionein IIA promoter and other key stress response elements by ursodeoxycholate in HepG2 cells: relevance to the cytoprotective function of ursodeoxycholate

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Antioxidant properties of ursodeoxycholic acid.

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Enhanced hepatic Nrf2 activation after ursodeoxycholic acid treatment in patients with primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Dysregulation of glutathione synthesis during cholestasis in mice: molecular mechanisms and therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Ursodeoxycholic acid induces glutathione synthesis through activation of PI3K/Akt pathway in HepG2 cells

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Ursodeoxycholic acid stimulates Nrf2-mediated hepatocellular transport, detoxification, and antioxidative stress systems in mice

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Nuclear DNA fragmentation and expression of Bcl-2 in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

T cell targeting and phagocytosis of apoptotic biliary epithelial cells in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Effect of tauroursodeoxycholic acid on endoplasmic reticulum stress-induced caspase-12 activation

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Inhibition of the MAPK and PI3K pathways enhances UDCA-induced apoptosis in primary rodent hepatocytes

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Tauroursodeoxycholic acid protects rat hepatocytes from bile acid-induced apoptosis via activation of survival pathways

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Modulation of nuclear steroid receptors by ursodeoxycholic acid inhibits TGF-beta1-induced E2F-1/p53-mediated apoptosis of rat hepatocytes.

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Plasma cells and the chronic nonsuppurative destructive cholangitis of primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Ursodeoxycholic acid reduces CpG-induced IgM production in patients with primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Immunomodulatory effects of ursodeoxycholic acid on immune responses

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Ursodeoxycholic acid protects concanavalin A-induced mouse liver injury through inhibition of intrahepatic tumor necrosis factor-alpha and macrophage inflammatory protein-2 production.

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Plant lectins are novel Toll-like receptor agonists

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Curcumin attenuates Concanavalin A-induced liver injury in mice by inhibition of Toll-like receptor (TLR) 2, TLR4 and TLR9 expression

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Molecular determinants of crosstalk between nuclear receptors and toll-like receptors.

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Bile salts control the antimicrobial peptide cathelicidin through nuclear receptors in the human biliary epithelium

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Vitamin D3 down-regulates monocyte TLR expression and triggers hyporesponsiveness to pathogen-associated molecular patterns.

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Liver autoimmunity triggered by microbial activation of natural killer T cells

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Ursodeoxycholic acid corrects defective natural killer activity by inhibiting prostaglandin E2 production in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Role of hepatocytes in direct clearance of lipopolysaccharide in rats

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

On the role and fate of LPS-dephosphorylating activity in the rat liver.

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Abnormal accumulation of endotoxin in biliary epithelial cells in primary biliary cirrhosis and primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Biliary innate immunity in the pathogenesis of biliary diseases

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Periductal interleukin-17 production in association with biliary innate immunity contributes to the pathogenesis of cholangiopathy in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Cholangiopathy with respect to biliary innate immunity

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Immune response to lipopolysaccharide in primary biliary cirrhosis and autoimmune diseases

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Loss of CFTR affects biliary epithelium innate immunity and causes TLR4-NF-κB-mediated inflammatory response in mice

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Ursodeoxycholic acid modifies gut-derived endotoxemia in neonatal rats

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Protective effect of the intravenous administration of ursodeoxycholic acid against endotoxemia in rats with obstructive jaundice

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Functional modulation of the glucocorticoid receptor and suppression of NF-kappaB-dependent transcription by ursodeoxycholic acid

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Anti-inflammatory effects of phosphatidylcholine

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Effects of Ursodeoxycholate and cholate feeding on liver disease in FVB mice with a disrupted mdr2 P-glycoprotein gene.

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Partial characterization of cytoprotective mechanisms of lecithin against bile salt-induced bile duct damage

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Effects of long-term ursodeoxycholate administration on expression levels of secretory low-molecular-weight phospholipases A2 and mucin genes in gallbladders and biliary composition in patients with multiple cholesterol stones.

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Low phospholipid associated cholelithiasis: association with mutation in the MDR3/ABCB4 gene

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Novel biotransformation and physiological properties of norursodeoxycholic acid in humans.

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice.

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Conjugation is essential for the anticholestatic effect of NorUrsodeoxycholic acid in taurolithocholic acid-induced cholestasis in rat liver.

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Nuclear receptors in human immune cells: expression and correlations.

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Regulation of ileal bile acid-binding protein expression in Caco-2 cells by ursodeoxycholic acid: role of the farnesoid X receptor

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

beta-Klotho and FGF-15/19 inhibit the apical sodium-dependent bile acid transporter in enterocytes and cholangiocytes

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

The orphan nuclear receptor, shp, mediates bile acid-induced inhibition of the rat bile acid transporter, ntcp

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor.

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Regulation of CYP3A4 by the bile acid receptor FXR: evidence for functional binding sites in the CYP3A4 gene

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

FXR induces the UGT2B4 enzyme in hepatocytes: a potential mechanism of negative feedback control of FXR activity

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Dehydroepiandrosterone sulfotransferase gene induction by bile acid activated farnesoid X receptor

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Role of farnesoid X receptor in determining hepatic ABC transporter expression and liver injury in bile duct-ligated mice

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Selective Activation of Nuclear Bile Acid Receptor FXR in the Intestine Protects Mice Against Cholestasis

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Dual farnesoid X receptor/TGR5 agonist INT-767 reduces liver injury in the Mdr2-/- (Abcb4-/-) mouse cholangiopathy model by promoting biliary HCO⁻₃ output

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

The human Na+-taurocholate cotransporting polypeptide gene is activated by glucocorticoid receptor and peroxisome proliferator-activated receptor-gamma coactivator-1alpha, and suppressed by bile acids via a small heterodimer partner-dependent mechan

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

The bile acid sensor farnesoid X receptor is a modulator of liver immunity in a rodent model of acute hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

VPAC1 expression is regulated by FXR agonists in the human gallbladder epithelium

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Alpha-crystallin is a target gene of the farnesoid X-activated receptor in human livers

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity.

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

Ursodeoxycholic acid amides as novel glucocorticoid receptor modulators.

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970015-3

7 January 2021

10.1016/S2210-7401(12)70015-3

Identifiers

DOI

1 reference

27 August 2017

1 reference

PubMed ID

23141891